Morgan Stanley’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-667,064
| Closed | -$7.47M | – | 6846 |
|
|
2017
Q3 | $7.47M | Buy |
667,064
+170,244
| +34% | +$1.88M | ﹤0.01% | 2570 |
|
|
2017
Q2 | $5.46M | Buy |
496,820
+143,519
| +41% | +$1.44M | ﹤0.01% | 2747 |
|
|
2017
Q1 | $3.46M | Sell |
353,301
-34,703
| -9% | -$347K | ﹤0.01% | 3268 |
|
|
2016
Q4 | $4.19M | Sell |
388,004
-2,035
| -0.5% | -$20.3K | ﹤0.01% | 3185 |
|
|
2016
Q3 | $4M | Sell |
390,039
-40,110
| -9% | -$437K | ﹤0.01% | 2889 |
|
|
2016
Q2 | $5.62M | Sell |
430,149
-87,445
| -17% | -$1.15M | ﹤0.01% | 2507 |
|
|
2016
Q1 | $5.69M | Sell |
517,594
-364,558
| -41% | -$3.24M | ﹤0.01% | 2407 |
|
|
2015
Q4 | $8.12M | Sell |
882,152
-30,445
| -3% | -$255K | ﹤0.01% | 2187 |
|
|
2015
Q3 | $6.33M | Buy |
912,597
+259,588
| +40% | +$2.22M | ﹤0.01% | 2436 |
|
|
2015
Q2 | $6.41M | Buy |
653,009
+264,200
| +68% | +$2.41M | ﹤0.01% | 2575 |
|
|
2015
Q1 | $3.44M | Buy |
388,809
+17,512
| +5% | +$139K | ﹤0.01% | 3099 |
|
|
2014
Q4 | $3.25M | Buy |
371,297
+1,927
| +0.5% | +$15.6K | ﹤0.01% | 3135 |
|
|
2014
Q3 | $2.54M | Buy |
369,370
+303,815
| +463% | +$1.82M | ﹤0.01% | 3235 |
|
|
2014
Q2 | $344K | Buy |
65,555
+52,634
| +407% | +$256K | ﹤0.01% | 4854 |
|
|
2014
Q1 | $58K | Sell |
12,921
-21,613
| -63% | -$104K | ﹤0.01% | 5653 |
|
|
2013
Q4 | $174K | Buy |
34,534
+6,476
| +23% | +$31.2K | ﹤0.01% | 5090 |
|
|
2013
Q3 | $142K | Sell |
28,058
-180,134
| -87% | -$1M | ﹤0.01% | 5003 |
|
|
2013
Q2 | $1.03M | Buy |
+208,192
| New | +$991K | ﹤0.01% | 3704 |
|
Morgan Stanley's SCLN Position: Q4 2017 in Review
Morgan Stanley sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 667,064 shares — an estimated $7.47M sold.
Morgan Stanley first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $8.12M in Q4 2015. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Morgan Stanley reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Morgan Stanley sold 667,064 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $7.47M.
- Morgan Stanley first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Morgan Stanley's Sciclone Pharmaceuticals Inc position peaked at $8.12M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Morgan Stanley's 13F filing for Q4 2017, filed 14 Feb 2018.